|
|
 |
|
Viewing report
|
|
|
|
European Coronary Stents Markets
Frost & Sullivan, Dec 2005
Budgetary Restraints Affect Growth of Drug Eluting Stents
Drug eluting stents (DES) represent one of the most exciting discoveries made in the field of interventional cardiology. Unique design, pharmacological agents and the drug delivery vehicle of these revolutionary medical devices offer significant advantages over bare metal stents (BMS). However, with the average prices of BMS ranging between $400-800, which is almost half that of DES, these stents score over DES in terms of cost. This is a strong influencing factor for governments to choose BMS over DES, despite the many advantages of the latter. Faced with rising healthcare costs, governments are compelled to curtail hospital budgets. Restricted purchasing power of hospitals combined with a lack of reimbursements has limited the use of DES in Europe, with more than 50 per cent of clinical procedures continuing to use BMS. Increased uptake of DES calls for ongoing clinical trials to highlight the benefits of these stents, especially for certain indications. Manufacturers must also strive to reduce prices of DES; this could help drive sales volumes and ensure repeat purchases.
This Frost & Sullivan research service provides an in-depth analysis of the European coronary stents market, evaluating its business potential in seven key regions of Europe. It discusses the major challenges, drivers and restraints affecting the market and provides strategic recommendations to overcome these challenges. The study includes a detailed assessment of the existing competitive structure and the current market shares of key participants.
Need to Produce Stents that Meet Safety Standards
The safety of the stents currently in the market is a key challenge facing manufacturers. With healthcare providers under pressure to improve levels of service and meet patients’ demands, government officials have started imposing strict safety standards for medical devices and periodical safety reviews by governments have become the norm in the region.
Coronary stents are used in highly delicate cardiac procedures and therefore, it is critical that they do not cause any additional complications to the patient. However, the biocompatibility and deliverability of DES are crucial in ensuring the efficacy of the procedure. 'A major concern in this respect is the thrombogenocity of these devices,' remarks the analyst of this research service. 'Many believe that the polymeter in DES, which releases the drug over time, plays a pivotal role in the appearance of late thrombosis; however, this is an area which needs to be examined further.'
Drug Therapy Provides Strong Competition to Coronary Stents
While coronary stents have successfully addressed complications such as stenosis and occlusion, problems such as restenosis and thrombosis are sources of much concern in the interventional cardiology industry. Stents manufacturers face stiff competition from pharmaceutical companies that have developed drugs, which are effectively addressing such problems. 'Pharmacological agents have the ability to reduce stenosis, prevent or dissolve thrombi and dilate arteries at various developmental stages,' notes the analyst. 'Drug treatments are significantly more cost-effective than surgical procedures and therefore pose a strong challenge to the development of the coronary stents market.'
Drug companies also have well-developed distribution channels and have gained the loyalty of clinicians. Manufacturers of medical devices must attempt to change such loyalties by raising awareness of the advantages of minimally invasive procedures compared to existing alternatives such as drug therapy.
Customers who bought this item also bought
Europe Coronary Stents Market: Revival of Drug Eluting Stents to Drive Growth
US Coronary Stents Market: Revival of Drug Eluting Stents to Drive Growth
U.S. Coronary Stents Markets 2007
Coronary Stents - Global Market Trends
Coronary Stents - Global Market Trends
Coronary Stents - Global Strategic Business Report
European Markets for Peripheral Stents
Japan Interventional Cardiology Devices: Coronary Stents to Drive Growth
Drug Eluting Stents – Technology & Market Forecast
Drug-Eluting Stents - Global Strategic Business Report
Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse Events With Drug-Eluting Stents Demand A New Safety Standard
U.S. Market for Drug-Eluting & Bare Metal Stents 2009
|
|
|
|
